| European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol A Bataller, A Garrido, F Guijarro, G Oñate, M Diaz-Beyá, M Arnan, ... Blood advances 6 (4), 1193-1206, 2022 | 27 | 2022 |
| Risk factors for mortality in hematopoietic stem cell transplantation recipients with bloodstream infection: points to be addressed by future guidelines P Puerta-Alcalde, M Chumbita, P Charry, S Castaño-Díez, C Cardozo, ... Transplantation and Cellular Therapy 27 (6), 501. e1-501. e6, 2021 | 13 | 2021 |
| Safety of COVID-19 vaccination in patients with clonal mast cell disorders M Ruano-Zaragoza, LV Carpio-Escalona, M Diaz-Beya, ... The Journal of Allergy and Clinical immunology. In Practice 10 (5), 1374, 2022 | 9 | 2022 |
| Real-world data on chronic myelomonocytic leukemia: Clinical and molecular characteristics, treatment, emerging drugs, and patient outcomes S Castaño-Díez, M López-Guerra, C Bosch-Castañeda, A Bataller, ... Cancers 14 (17), 4107, 2022 | 7 | 2022 |
| The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting … LG Rodríguez-Lobato, A Martínez-Roca, S Castaño-Díez, ... Plos one 15 (11), e0241778, 2020 | 6 | 2020 |
| Germ line variants in patients with acute myeloid leukemia without a suspicion of hereditary hematologic malignancy syndrome F Guijarro, M López-Guerra, J Morata, A Bataller, S Paz, ... Blood Advances 7 (19), 5799-5811, 2023 | 5 | 2023 |
| Acquired erythropoietic uroporphyria secondary to myeloid malignancy: A case report and literature review. L Serra‐García, D Morgado‐Carrasco, AI Pérez‐Valencia, ... Photodermatology, Photoimmunology & Photomedicine 38 (1), 2022 | 4 | 2022 |
| Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML … C Jiménez-Vicente, A Martínez-Roca, H Pomares, S Castaño-Diez, ... Leukemia Research 135, 107403, 2023 | 1 | 2023 |
| Chronic Myelomonocytic Leukemia (CMML) with AML Typical Mutations (NPM1, FLT3 or CEBPA) Identify a High-Risk CMML Group Independent of Molecular-Cpss S Castaño-Díez, I Zugasti, X Calvo, F Schulz, AA Pita, E Mora, JF Falantes, ... Blood 142, 3231, 2023 | 1 | 2023 |
| Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study I Zugasti, S Castaño-Díez, D Esteban, AA Pita, H Pomares, AP González, ... Blood 142, 1858, 2023 | 1 | 2023 |
| Characteristics and long‐term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic S Castaño‐Díez, H Pomares, D Esteban, F Guijarro, C Jiménez‐Vicente, ... British Journal of Haematology, 2023 | 1 | 2023 |
| Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based … F Guijarro, A Bataller, M Diaz-Beyá, A Garrido, C Coll-Ferrà, S Vives, ... Bone Marrow Transplantation 57 (8), 1304-1312, 2022 | 1 | 2022 |
| Infrequent Presentations of Chronic NPM1-Mutated Myeloid Neoplasms: Clinicopathological Features of Eight Cases from a Single Institution and Review of the … S Castaño-Díez, F Guijarro, M López-Guerra, AI Pérez-Valencia, ... Cancers 16 (4), 705, 2024 | | 2024 |
| Next Generation Sequencing Study of clonal Evolution in AML Shows Mutations in RAS-MAPK Signaling Pathway as an Emergent Mechanism of Progression in Low-Intensity Treatments C Jiménez-Vicente, M Lopez-Guerra, AI Pérez-Valencia, D Munarriz, ... Preprints, 2024 | | 2024 |
| Validation of ELN 2022 Risk Classification in Patients Diagnosed with AML Undergoing Allogeneic Hematopoietic Cell Transplantation C Jimenez-Vicente, P Charry, M Suarez-Lledo, BM Muñoz, ... Blood 142, 4230, 2023 | | 2023 |
| Allogeneic Hematopoietic Cell Transplantation with Sequential-Based Conditioning in Refractory/Relapsed Acute Myeloid Leukemia: Experience from a Single Institution C Tolosa-Ridao, P Charry, M Suarez-Lledo, D Esteban, M Díaz-Beyá, ... Blood 142, 3550, 2023 | | 2023 |
| Clinical Characterization of Fusion Genes in Acute Myeloid Leukemia without Recurrent Genetic Abnormalities F Guijarro, M Dabad, M López-Guerra, AB Torralba, S Castaño-Díez, ... Blood 142, 6008, 2023 | | 2023 |
| Evaluation of the Use of Post-Transplant Cyclophosphamide in Patients Diagnosed of Myelodysplastic Syndrome Who Undergo Allogenic Hematopoietic Cell Transplantation C Tolosa-Ridao, P Charry, S Castaño-Díez, M Suarez-Lledo, BM Muñoz, ... Blood 142, 7018, 2023 | | 2023 |
| PB1846: MANAGEMENT OF PATIENTS TREATED WITH VENETOCLAX WITH HYPOMETHYLATING AGENTS: LONG-TERM INCIDENCE OF CYTOPENIAS AND INFECTIONS A Guardia-Torrelles, C Jimenez-Vicente, AM Roca, S Castaño-Díez, ... HemaSphere 7 (S3), e32922f1, 2023 | | 2023 |
| Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: MUTATIONAL PROFILE ENABLES THE IDENTIFICATION OF A HIGH RISK SUBGROUP IN MYELODYSPLASTIC SYNDROMES WITH … SMT Castelló, S Castaño-Díez, AV Ramiro, E Such, M Arnan, F Solé, ... Leukemia Research 128, 107189, 2023 | | 2023 |
